http://www.mmm-online.com/multiple-sclerosis/topic/15401/ Articles tagged with Multiple Sclerosis from Medical Marketing and Media MMM mmmsubs@haymarketmedia.com no AbbVie lays off 100 R&D staff; Teva looks to expand Copaxone footprint; researchers crack HIV protein code; monitors may be misleading diabetics and a prototype sensor turns iPhones into virus hunters. http://www.mmm-online.com/business-briefs-abbvie-teva-hiv-diabetes-iphone/article/295475/ Thu, 30 May 2013 15:59:52 GMT AbbVie lays off 100 R&D staff; Teva looks to expand Copaxone footprint; researchers crack HIV protein code; monitors may be misleading diabetics and a prototype sensor turns iPhones into virus hunters. MMM Execs unveiled 10% sales growth and told investors the safety news does not implicate their just-approved MS pill. http://www.mmm-online.com/biogen-reports-sales-jump-backs-tolerability-of-new-ms-pill/article/290570/ Thu, 25 Apr 2013 18:07:07 GMT Execs unveiled 10% sales growth and told investors the safety news does not implicate their just-approved MS pill. MMM Doctors call out Novartis on drug prices; Aubagio shows strong top-line data in trials; and overseas docs increasingly turn to digital. http://www.mmm-online.com/business-briefs-docs-question-gleevec-price-sanofi-pill-may-delay-ms-onset/article/290560/ Thu, 25 Apr 2013 17:17:27 GMT Doctors call out Novartis on drug prices; Aubagio shows strong top-line data in trials; and overseas docs increasingly turn to digital. MMM MS patients have an "insatiable appetite" for information about treatments online, particularly the new class of oral treatments, whose manufacturers could be doing more to prep them for switch conversations, a survey suggests. http://www.mmm-online.com/ms-patients-hungry-for-info-on-orals-says-survey/article/284423/ Thu, 14 Mar 2013 17:42:06 GMT MS patients have an "insatiable appetite" for information about treatments online, particularly the new class of oral treatments, whose manufacturers could be doing more to prep them for switch conversations, a survey suggests. MMM A study in the New England Journal of Medicine said patients had a significant relapse reduction over two years on the oral drug. http://www.mmm-online.com/biogen-brags-of-phase-iii-data-for-would-be-aubagio-rival-oral-ms-drug/article/259994/ Thu, 20 Sep 2012 18:27:47 GMT A study in the New England Journal of Medicine said patients had a significant relapse reduction over two years on the oral drug. MMM The move expands patient options, but industry watchers tell MM&M it's not going to spur a radical change in treatment. http://www.mmm-online.com/fda-approves-sanofi-daily-ms-pill/article/258891/ Thu, 13 Sep 2012 17:00:42 GMT The move expands patient options, but industry watchers tell MM&M it's not going to spur a radical change in treatment. MMM A cancer drug being developed by Medivation and Astellas gets its closeup, and Teva launches in to Phase III trials of its oral MS drug laquinimod. http://www.mmm-online.com/company-news-medivationastellas-and-teva/article/253896/ Wed, 08 Aug 2012 16:32:44 GMT A cancer drug being developed by Medivation and Astellas gets its closeup, and Teva launches in to Phase III trials of its oral MS drug laquinimod. MMM Five patients will document their challenges and triumphs online in this project developed by the National MS Society and Sanofi's Genzyme unit. http://www.mmm-online.com/genzyme-backed-program-to-chronicle-lives-of-patients-with-ms/article/253220/ Thu, 02 Aug 2012 19:49:14 GMT Five patients will document their challenges and triumphs online in this project developed by the National MS Society and Sanofi's Genzyme unit. MMM Biogen Idec and Elan, which market Tysabri for multiple sclerosis, won approval to add new safety information to the drug's label that could boost sales by helping doctors avoid a serious adverse event. http://www.mmm-online.com/tysabri-gets-boost-from-label-change-new-diagnostic/article/224378/ Mon, 23 Jan 2012 22:23:18 GMT Biogen Idec and Elan, which market Tysabri for multiple sclerosis, won approval to add new safety information to the drug's label that could boost sales by helping doctors avoid a serious adverse event. MMM